UFUlises Ferrandiz

Ulises Ferrandiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulises Ferrandiz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Albert Font

    Medical Oncology Department, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, 08916 Badalona, Spain

    1 shared publication
  • Jose F Suarez

    Urology Department, Bellvitge University Hospital, Hospitalet de LLobregat, Spain

    1 shared publication
  • Josep Comet

    Urology Department, University Hospital Josep Trueta, Girona, Spain

    1 shared publication
  • Josep Maria Piulats

    Catalan Institute of Oncology, Medical Oncology Department, Bellvitge University Hospital, Hospitalet De Llobregat, Spain

    1 shared publication
  • Juan Carlos Pardo

    Catalan Institute of Oncology, Medical Oncology Department, University Hospital Germans Trias I Pujol, Badalona, Spain

    1 shared publication
  • Lauro Sumoy

    High Content Genomics and Bioinformatics (HCGB)-Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain

    1 shared publication

Latest Publications

  • Open Access

    PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

    by Sofia España, Maria Ochoa de Olza, Nuria Sala, Josep Maria Piulats, Ulises Ferrandiz, Olatz Etxaniz, Lucia Heras, Oscar Buisan, Juan Carlos Pardo, Jose F Suarez, et al.

    Background: Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need to identify patients more likely to benefit from AA. Parameters linked to prostate-specific antigen (PSA) kinetics are promising prognostic markers. We have examined clinical and PSA-related factors potentially associated with overall survival (OS) in patients treated with AA. Methods: Between 2011 and 2014, 104 patients with mCRPC treated with AA after progression to docetaxel at centers of the Catalan Institute of Oncology were included in this retrospective study. Patients were assessed monthly. Baseline characteristics and variables related to PSA kinetics were included in univariate and multivariate analyses of OS. Results: Median OS was 16.4 months (range 12.4– 20.6) for all patients. The univariate analysis identified the following baseline characteristics as significantly associated with OS: ECOG PS, location of metastases, time between starting androgen deprivation therapy and starting AA, time between stopping docetaxel treatment and starting AA, neutrophil-lymphocyte ratio (NLR), alkaline phosphatase levels, and PSA levels. Factors related to PSA kinetics associated with longer OS were PSA response > 50%, early PSA response (> 30% decline at four weeks), PSA decline > 50% at week 12, PSA nadir < 2.4ng/mL, time to PSA nadir > 140 days, the combination of PSA nadir and time to PSA nadir, and low end-of-treatment PSA levels. The multivariate analysis identified ECOG PS (HR 37.46; p< 0.001), NLR (HR 3.7; p< 0.001), early PSA response (HR 1.22; p=0.002), and time to PSA nadir (HR 0.39; p=0.002) as independent prognostic markers. Conclusion: Our results indicate an association between PSA kinetics, especially early PSA response, and outcome to AA after progression to docetaxel. Taken together with other factors, lack of an early PSA response could identify patients who are unlikely to benefit from AA and who could be closely monitored with a view to offering alternative therapies.